Low expression of SLC39A1 decreases the level of Zn2+ in prostate cancer tissue, thereby reducing the level of citrate, and ultimately resulting in the malignant progression of prostate cancer [14, 15]. This evidence concerns the gene SLC39A1 and prostate cancer.